NanoViricides Inc. (NNVC)

[changes_iv]

It has been 35 days from 60---any updates from your government?

Countdown to catastrophe: UN warns world has just 60 DAYS to stop Ebola outbreak
Oct 15, 2014 12:19
By Sam Adams

The organisation says the virus is 'running faster than us and it is winning the race' as it continues to ravage West Africa and spread across the globe

http://www.mirror.co.uk/news/world-news/countdown-catastrophe-un-warns-world-4441661

"Face, nose, mouth, everything."
...
MailOnline further reported:

On Tuesday evening, a Hazmat team was back on the scene to run tests, setting up across the street from the hair salon.

It was not clear why Amy Professional Hair Braiding would not have been evacuated until it was certain the woman did not have Ebola.

The salon was decontaminated late on Tuesday by a Hazmat crew.

According to a source who was on the scene, the incident occurred just after 3pm on Tuesday.

Emergency medical response personnel pronounced the woman dead at the scene.

"We were in the building and all the sudden the other owner came from the store and he said somebody dropped dead in their store," said a man named Costa, who works next door to the salon. He added that he ran into the salon and found the woman lying on the floor.

When asked by reporters where she was bleeding, he answered: "Face, nose, mouth, everything."

'Non-Ebola incident'?

FDNY personnel in hazmat gear said they donned protective equipment before going into the store in response to a "fever travel illness." The emergency medical personnel also said that they found a "clean scene" -- no body fluids leaving the woman's body at all, which of course does not square with eyewitness accounts.

In October, the FDNY issued a memo instructing all personnel to refer to Ebola in more vague terms, such as "fever travel incident."

New York City health authorities were on the scene to take blood samples from the woman, the MailOnline report said. Those personnel, along with emergency responders, were all run through decontamination processes.

In a statement to ABC News, an unnamed NYC health official said:

Earlier today, an individual who came to the U.S. from one of the three Ebola-impacted nations in West Africa within last three weeks died of an apparent non-Ebola condition. This individual at no time showed any symptoms of Ebola. However, due to travel history and an abundance of caution, an Ebola test will be performed on this individual's remains. Test results are expected later tonight or early tomorrow morning...

Sources:

http://www.naturalnews.com

http://www.dailymail.co.uk

http://abcnews.go.com

http://www.naturalnews.com

Ebola Spreading Intensely In Sierra Leone As Death Toll Rises: WHO

By Stephanie Nebehay

GENEVA, Nov 19 (Reuters) - The toll in the Ebola epidemic has risen to 5,420 deaths out of 15,145 cases in eight countries, the World Health Organization (WHO) said on Wednesday, with transmission of the deadly virus still "intense and widespread" in Sierra Leone.

The figures, through Nov. 16, represent a jump of 243 deaths and 732 cases since those issued last Friday, and cases continue to be under-reported, the WHO said in its latest update.

Sierra Leone, a former British colony, confirmed 533 new cases in the week to Nov. 16, it said, accounting for much of the increase. It also reported 63 deaths since last Friday.

"Much of this was driven by intense transmission in the country's west and north," the WHO said.

The capital Freetown, which accounted for 168 new confirmed cases, and nearby Port Loko were particularly hard-hit.

A Cuban doctor infected with Ebola in Sierra Leone will be flown to Switzerland in the next 48 hours for hospitalization in Geneva, Swiss health authorities said on Wednesday. He is the first Cuban known to have contracted the disease.

The outbreaks in Guinea and Liberia currently appear to be driven by intense transmission in several key districts, the WHO said, citing N'Zerekore and Macenta in Guinea and Montserrado in Liberia, which includes the capital Monrovia.

In the three most affected countries - Guinea, Liberia and Sierra Leone - 1,159 beds are now operational in 18 Ebola treatment centers, or one-quarter percent of beds planned, according to the U.N. agency. But only 13 percent of Ebola patients in Sierra Leone are in isolation, its figures show.

"As this number increases, so does the capacity to isolate patients and prevent further transmission of the disease."

Ebola Mutation: Lack Of Virus Samples In US Hampers Efforts To Track Its Changes

Samples of Ebola are in short supply for U.S. scientists who require a fresh, steady stock of the virus to track its changes and to plan ahead for new drugs and vaccines. Similar to the flu virus, Ebola mutates, however slightly, as it spreads, and keeping up with those changes is key to stopping new infections and heading off future outbreaks, according to Reuters.

"No one really knows right now what has the virus mutated to or if it has mutated," Charles Chiu, a microbiologist and infectious disease expert at the University of California, San Francisco, told Reuters. “We're not going to be able to determine in advance whether or not it has changed to a form where it might evade diagnostic assays or might render current vaccines or drugs ineffective” without new samples of the virus, he said.

Moving Ebola samples safely from one place to another is complicated, and transport companies have been wary of working with Ebola because of growing concerns about a U.S. spread of the virus. Doctors in Guinea, Liberia and Sierra Leone, where infections have topped 13,500 people, have been slow to hand over samples of Ebola, scientists told Reuters, which means U.S. disease specialists studying the virus at eight major research institutions are not getting the latest specimens.

As Ebola continues to spread across West Africa, it has more chances to change and adapt. Scientists identified 341 mutations of the virus as of late August, according to a study published that month in Science. One fear is that the virus could become more transmissible by becoming less pathogenic. A virus that sickens and kills its victims more slowly would leave more time for patients to infect others, National Geographic reported. The biggest nightmare, scientists have said, would be if the virus went airborne, something experts believe is highly unlikely but not impossible.

http://www.ibtimes.com/ebola-mutation-lack-virus-samples-us-hampers-efforts-track-its-changes-1719267

Obama Indemnifies Gov’t Contractors From Damages Arising from Importing Ebola to US
...
An unnamed spokesperson for the agency responded: “Yes. The indemnification applies only to the extent that the claim, loss, or damage arises out of or results from exposure to Ebola in the course of performance of a contract and exceeds applicable insurance coverage.”

In other words, if a Company A employee contracts Ebola while working in West Africa, brings the disease back to the United States, is not quarantined and ends up infecting members of the general public, Company A is protected from any damages arising from lawsuits by these secondary victims.

According to the USAID spokesperson, employees of these contracted companies "provide essential services, including medical and non-medical management of Ebola patients."

In his memorandum, Obama justified his actions by citing Public Law 85-804, which allows the president to give any federal agency or department connected to national security the authority to enter into, amend or modify contracts with private companies in order to “facilitate the national defense.”

http://www.cnsnews.com/news/article/brittany-m-hughes/obama-indemnifies-gov-t-contractors-damages-arising-importing-ebola

Seems to me NanoViricides, Inc. is moving forward in several fronts:

FluCide

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that its “Injectable FluCide™” drug candidate for severe influenza has been chosen as one of the “Top Ten Infectious Diseases Projects to Watch” by a panel of industry experts assembled by Informa and the publishers of In Vivo, Startup and The Pink Sheet. As a result of this selection, Anil R. Diwan, PhD, President and Chairman of the Company, will give a company presentation at the Therapeutic Area Partnerships Meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston (www.tapartnerships.com). The presentation is scheduled for 4:20pm Eastern time, today, November 20, 2014.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.”

Ebola

The Company reports that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate.

In particular, the synthesis of anti-Ebola drug candidates is progressing satisfactorily. The Company has recently reported that it has signed a “Cooperative Research and Development Agreement - Materials Transfer Agreement (CRADA-MTA)” with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) for biological testing of these candidates. The Company is working expeditiously on its anti-Ebola program at present, in order to develop an effective drug candidate that may be available in response to the current Ebola epidemic crisis. The Company has the ability to produce sufficient quantities of a successful drug candidate for potential field use.


The cGMP Pilot Plant in Shelton, CT will soon be validated (IMO)

The Company has developed a state-of-the-art nanomedicines manufacturing facility that will be capable of producing any of the Company’s drug candidates in a cGMP-compliant manner in multi-kilogram quantities. This facility will be able to provide the cGMP clinical drug substances for the Company’s future human clinical studies. (“c-GMP”= current Good Manufacturing Practices). The Company’s Board of Directors has authorized acquisition of this facility from Inno-Haven, LLC, rather than leasing it. The acquisition process is in the due diligence phase at present, and is expected to be concluded soon.

===========================================

Government To Fly Illegals From Honduras Straight To The U.S. So They Can Avoid Dangerous Journey! Will the passengers be screened for Ebola or other disease and propensity to violence?